Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 1431 to 1440 of 2733 total matches.
The Reflotron For Office Chemistry
The Medical Letter on Drugs and Therapeutics • Oct 06, 1989 (Issue 802)
for the Ektachem System DT60 and DTSC. Reflotron test strips cost $1.23 to $1.87 each, compared
to $1.25 to $2.10 ...
The Reflotron (Boehringer Mannheim), a desk-top colorimetric reflectance analyzer that weighs 12 pounds, can do clinical chemistry tests on 30 l of whole blood, plasma or serum, using multilayered strips containing dry chemicals. A single test takes two to three minutes.
Ethanolamine Oleate For Esophageal Varices
The Medical Letter on Drugs and Therapeutics • Nov 03, 1989 (Issue 804)
Engl J Med, 320:1393, 1469, May 25 and June 1,
1989). Ethanolamine oleate 5% (Ethamolin − Glaxo ...
Endoscopic injection of sclerosing agents is now widely accepted as a primary treatment for bleeding esophageal varices (J Terblanche et al, N Engl J Med, 320:1393, 1469, May 25 and June 1, 1989). Ethanolamine oleate 5% (Ethamolin - Glaxo), a sclerosing agent that has been available in Canada and abroad for many years, was recently approved for this indication by the US Food and Drug Administration (FDA).
Interferon for Chronic Viral Hepatitis
The Medical Letter on Drugs and Therapeutics • Jan 12, 1990 (Issue 809)
Intern Med, 147:1577, 1987; M
Schultz et al, Lancet, 1:1452, 1989).
The Medical Letter, Vol. 32 (Issue ...
Recombinant alpha interferon has been marketed in the USA for treatment of hairy-cell leukemia, genital warts, and AIDS-related Kaposi's sarcoma (Medical Letter, 28:78, 1986; 30:70, 1988). Recent reports indicate it may also be useful for treatment of chronic viral hepatitis. Recombinant alpha interferon is available as alfa-2a (Roferon-A - Roche) or alfa-2b (Intron A - Schering), which are identical except for one amino acid.
Tribenzor for Hypertension
The Medical Letter on Drugs and Therapeutics • Sep 06, 2010 (Issue 1346)
to control their blood pressure.1 Tribenzor (Daiichi
Sankyo), recently approved by the FDA for treatment ...
Many patients with hypertension require more than one drug to control their blood pressure. Tribenzor (Daiichi Sankyo), recently approved by the FDA for treatment of hypertension, combines the calcium channel blocker amlodipine (Norvasc, and others), the angiotensin receptor blocker (ARB) olmesartan (Benicar)and the most commonly prescribed diuretic, hydrochlorothiazide (HCTZ). Tribenzor is not approved for initial therapy, but is recommended for patients not adequately controlled on any 2-drug combination of a calcium channel blocker, an ARB or a diuretic.
Dalfampridine (Ampyra) for MS
The Medical Letter on Drugs and Therapeutics • Sep 20, 2010 (Issue 1347)
(Copaxone), mitoxantrone (Novantrone) and natalizumab
(Tysabri).1 Rituximab (Rituxan) and alemtuzumab ...
The FDA has approved the use of dalfampridine (4-aminopyridine; Ampyra – Acorda), a potassium
channel blocker, to improve walking speed in patients with multiple sclerosis (MS). Walking speed is considered
a reliable clinical measure of impairment in patients with MS.
Nitroglycerin Ointment (Rectiv) for Anal Fissure
The Medical Letter on Drugs and Therapeutics • Mar 19, 2012 (Issue 1386)
sphincter.1
STANDARD TREATMENT — The most effective
treatment for chronic anal fissure is a lateral ...
The FDA has approved the use of nitroglycerin ointment
0.4% (Rectiv – ProStrakan/Aptalis) for treatment
of moderate to severe pain associated with chronic
anal fissure; the same drug is marketed as Rectogesic
in Europe. Nitroglycerin ointment 2% (Nitro-Bid) is
available in the US for prevention of angina.
Enzalutamide (Xtandi) for Prostate Cancer (online only)
The Medical Letter on Drugs and Therapeutics • Mar 04, 2013 (Issue 1411)
of enzalutamide,
while itraconazole, a strong CYP3A4 inhibitor,
only increased them 1.3-fold. Enzalutamide ...
The FDA has approved enzalutamide (en za loo’ ta
mide; Xtandi – Astellas/Medivation) for oral treatment
of metastatic castration-resistant prostate cancer in
patients previously treated with docetaxel (Taxotere,
and generics). It is the second oral drug approved for
this indication; abiraterone acetate (Zytiga), which is
also approved for first-line use, was the first.
Cabazitaxel (Jevtana), which is given parenterally, has
a similar indication.
Lanadelumab (Takhzyro) for Prevention of Hereditary Angioedema (online only)
The Medical Letter on Drugs and Therapeutics • Mar 11, 2021 (Issue 1619)
) in 125
adolescents and adults with type 1 or 2 HAE who were
randomized to receive SC injections ...
The FDA has approved lanadelumab-flyo (Takhzyro –
Takeda), a subcutaneously-administered plasma
kallikrein inhibitor, for prevention of hereditary
angioedema (HAE) attacks in adults and children
≥12 years old. Lanadelumab is the third drug to be
approved for this indication; the human plasmaderived
C1 esterase inhibitors (C1INHs) Cinryze,
which is administered IV, and Haegarda, which is
given SC, have been available for years for HAE
prophylaxis in patients ≥6 years old.
Tramadol Oral Solution (Qdolo) for Pain
The Medical Letter on Drugs and Therapeutics • May 31, 2021 (Issue 1625)
opioid agonist and a weak serotonin and
norepinephrine reuptake inhibitor.1 It is metabolized
by CYP2D6 ...
The opioid agonist tramadol is now available in an oral
solution (Qdolo – Athena Bioscience) for management
of pain severe enough to require an opioid and for
which alternative treatment options are inadequate.
Tramadol has been available for years in immediate-release
tablets and capsules, extended-release
capsules (Ultram, and others), and in a fixed-dose
combination tablet with acetaminophen (Ultracet,
and generics).
Ryzneuta for Prevention of Febrile Neutropenia
The Medical Letter on Drugs and Therapeutics • Aug 19, 2024 (Issue 1709)
the duration of
chemotherapy-induced neutropenia and the
incidence of infection.1 As with pegfilgrastim ...
Efbemalenograstim alfa-vuxw (Ryzneuta – Evive), a
nonpegylated granulocyte colony-stimulating factor
(G-CSF) conjugated to an Fc fragment of human
IgG2, has been approved by the FDA to decrease
the incidence of infection, as manifested by febrile
neutropenia, in adults with nonmyeloid malignancies
receiving myelosuppressive chemotherapy that can
cause clinically significant febrile neutropenia. It is
the first nonpegylated, long-acting G-CSF to become
available in the US. Two pegylated, long-acting
G-CSFs, pegfilgrastim (Neulasta, and biosimilars)
and eflapegrastim (Rolvedon), are...
Med Lett Drugs Ther. 2024 Aug 19;66(1709):134-5 doi:10.58347/tml.2024.1709d | Show Introduction Hide Introduction
